You don't want any of this to happen so as soon as you are diagnosed get heparin going. I'm not medically trained but due to the research I'm reading I'm doing heparin.
Why I'm getting heparin. Heparin binds to cells at a site adjacent to ACE2, the portal for SARS-CoV-2 infection, and "potently" blocks the virus, which could open up therapy options.
Anticoagulation Again Shown to Improve Survival in COVID-19 Patients;-Mortality risk about 50% lower
But this research below suggests not due to bleeding risks. I'll take that risk since I've been on warfarin, aspirin and had Lovenox shots.
COVID-Related Strokes Especially Severe, Result in Worse Outcomes
The paragraph from there:
"On the other hand, in most patients with COVID-19 associated ischaemic stroke, very early anti-coagulation is probably not warranted as a strategy to prevent inpatient stroke recurrence, as this outcome is too uncommon to justify the increased risk of secondary haemorrhage," according to the group.(So you wait until the clots are severe before you do anti-coagulation. OK, not for me.)
You doctor better know the EXACT PROTOCOL to prevent these complications.
The latest here:
High mortality rate in COVID-19–associated stroke, analysis of risk factors
Why is there a disproportionate rate among black patients?
In a preliminary analysis of a North American neurovascular consortium comprising 14 comprehensive stroke centres in the USA and Canada, Dmytriw et al on p XXX suggest that rates of mortality with COVID-19–associated stroke are greater than in COVID-19 or stroke in otherwise. Importantly, African American/black patients experience greater rates of mortality when suffering stroke compared with other races in this cohort. While this group had greater rates of diabetes mellitus, higher LDL levels and higher sICH, there were no definite other differences between them. Lower rates of tPA and EVT administration approached significance, but it is unclear whether this will be borne out as the consortium grows.
The neurological insults associated with COVID-19 are becoming increasingly recognised.1 An initial report from China showed 4.6% of patients with COVID-19 had acute ischaemic stroke (10/219), and strokes were seen in those who were older, had more vascular risk factors and more severe COVID-19 infection.2 As we in Italy hurried to synthesise findings and respond to a national emergency, the pandemic subsumed New York City and a major stroke care system eventually reported that 65.6% of COVID-associated strokes were cryptogenic compared with 30.4% and 25.0% in contemporary and historic controls, respectively.3 Admission NIHSS and peak D-dimer were both consistently higher.
We understand from Millett et al in an investigation of COVID-19 impact on black communities that counties with higher proportions of black residents had more COVID-19 cases (RR 1.24, 95% CI 1.17 to 1.33).4 Indeed, they also identified a higher COVID-19 mortality (RR 1.18, 95% CI 1.00 to 1.40) and have reported that 20% of US counties are disproportionately black, which account for 52% of COVID-19 cases and 58% of COVID-19 deaths. The work by Price-Haywood et al has helped us to understand the mechanisms at play.5 The investigators analysed a total 3481 patients with COVID-19 in Louisiana (Ochsner Health), showing that 76.9% of hospitalisations and 70.6% of deaths associated with COVID-19 were black. After adjustment for differences in sociodemographic and clinical characteristics on admission, black race was not associated with higher in-hospital mortality. However, this depended on modelling differentially considered race only, covariates of age and sex, Charlson Comorbidity Index, low-income residence, obesity, insurance source, and admission vitals and laboratory studies. The authors note this may reflect racial differences in employment-associated risk, differences in prevalence of chronic comorbidities which increase the risk of severe illness, and the incidence of factors such as obesity and diabetes which were higher in the black population. However, these conditions are also higher among persons of lower education or low income across all race groups highlighting another potentially crucial factor.
As fatalities continue to be reported in both Italy and the USA, elucidation of a potential interaction between COVID-19 and stroke which explains elevated fatality rates is more pressing than ever. At the same time, sociodemographic evidence which allows us to understand and ultimately combat outcome inequity is also urgently needed.
No comments:
Post a Comment